Stock Ratings / Health Care / ATOS / options

AYTU (29) BYSI (34) TXMD (34) QNTM (46) ⌘ Pro Terminal →

Atossa Therapeutics Inc. (ATOS) Options Positioning, Max Pain & Unusual Sweeps

$2.17 -2.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.16

Atossa Therapeutics Inc. (ATOS) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $22.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATOS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Atossa Therapeutics Inc. (NASDAQ: ATOS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.17 (-2.69% 1D, market cap $22.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ATOS ranks #691 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATOS compare to AYTU and BYSI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATOS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AYTU (Aytu BioPharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $21.5M) and BYSI (BeyondSpring Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $21.2M). Among the 5-stock peer group, ATOS leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATOS?

▼

Per ATOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001488039), Atossa Therapeutics Inc. generated $0 in revenue, -$34.8M in net income, and -$29.8M in free cash flow against $47.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.16 (-0.67%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATOS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY ATOS SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 42.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.39+7.1% Next Q

Q2 (-2Q)

Grade D$2.56-4.3% Next Q

Q3 (-1Q)

Grade E$2.45-11.4% Next Q

Current

Grade D-$2.17-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATOS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATOS currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.41) and Max Pain ($2.28) forces dealer call-delta covering toward $15.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATOS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATOS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ATOS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ATOS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATOS)

✓Walkthrough of ATOS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATOS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.97%📐 HORIZONTAL RANGE

2026-11-02O $2.37H $2.37L $2.17C $2.17VOL 68.0K

RES: $3.16SUP: $1.68SMA50: $2.41SMA200: $3.91

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATOS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATOS Butterfly Map → + Track ATOS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ATOS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATOS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATOS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATOS)

Health Care Rank #691 of 1016 ⚔️ AYTU vs ATOS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATOS vs. AYTU, BYSI, TXMD, QNTM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Atossa Therapeutics Inc. (ATOS) ranks #691 by composite RQD confidence (35/100, grade D-) and #824 by equity capitalization ($22.3M). Within this direct 5-issuer industry benchmark cohort, ATOS leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with ATOS at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATOS ACTIVE Atossa Therapeutics Inc.	D-	35/100	—	—	-35.0%	-2.69%	$22.3M	Benchmark Subject
AYTU Aytu BioPharma Inc.	E	29/100	—	69.0%	-35.0%	-2.52%	$21.5M	/aytu-vs-atos →
BYSI BeyondSpring Inc.	E	34/100	—	—	-35.0%	+24.60%	$21.2M	/bysi-vs-atos →
TXMD TherapeuticsMD Inc.	E	34/100	—	—	-12.9%	-1.64%	$21.2M	/txmd-vs-atos →
QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D	46/100	—	—	—	-2.46%	$20.7M	/qntm-vs-atos →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001488039

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atossa Therapeutics Inc. (ATOS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$34.8M, operating cash flow of -$29.8M, and free cash flow of -$29.8M (-41.5% YoY). On the balance sheet, ATOS closed FY2025 with $47.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$34.8M	-$29.8M	-$29.8M	$47.6M	—
FY2024 (FY)	2024-12-31	$0	-$25.5M	-$21.0M	-$21.0M	$76.4M	—
FY2023 (FY)	2023-12-31	$0	-$30.1M	-$20.9M	-$20.9M	—	—

3. ATOS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ATOS compare to AYTU and BYSI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ATOS?

Where is ATOS trading relative to its 50-day, 200-day, and 52-week technical levels?

ATOS last traded at $2.17 (-2.69% on volume of 32,913 shares), positioning the stock -9.96% below its 50-day simple moving average ($2.41) and -44.50% below its 200-day simple moving average ($3.91). Across its 52-week range of $1.70 to $14.85, ATOS sits at the 3.6% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.90 to $2.44).

ATOS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ATOS's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ATOS.

Direct Sub-Reports: ATOS RQD Cockpit ATOS 12M Forecast ATOS Earnings & Move ATOS Dividends & DRIP ATOS Insiders & 13F ATOS Whale Options ATOS Profit Sankey ATOS News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ATOS — Atossa Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:38Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ATOS scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC of -35%; FCF yield of 0%); Whale 13F Flow at 4/20 (institutional accumulation and options positioning); Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 9/20 (Beta of 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z of 2.5; Piotroski F of 2/9; Debt/Equity of 0.5).

For a prospective investor, the weakest pillars are the cash engine and capital flow. A negative ROIC and zero FCF yield indicate that, per the reported financials, the business is not currently generating returns on invested capital or free cash flow. Institutional and insider flow scores are also low, meaning the rating reflects limited evidence of conviction from informed holders. The forensic balance sheet score is mid-range rather than strong: a Piotroski F of 2/9 is weak, while an Altman Z of 2.5 and Debt/Equity of 0.5 are not the primary concern in this dataset. The macro pillar is neutral, with Beta of 1.0. Any upside case would depend on cash-burn reduction, a change in flow dynamics, or non-operating catalysts; the source data does not establish a cash-generation path. Valuation cannot be anchored on earnings, since P/E and EV/EBITDA are unavailable and the company reports zero revenue.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-37.1M	$-34.8M	N/A	$-29.8M	$41.3M	N/A
FY 2024	$0.0M	$-27.6M	$-25.5M	N/A	$-21.0M	$71.1M	N/A
FY 2023	$0.0M	$-31.4M	$-30.1M	N/A	$-20.9M	N/A	N/A

Per the SEC financials, the company reported operating losses in each period, with FY 2025 operating income of $-37.1M and net income of $-34.8M. Margins are 0% for gross, operating, and net per the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating. Reported cash declined from $71.1M in FY 2024 to $41.3M in FY 2025, and debt is listed as N/A in the financials.

Recent Catalysts & News Wire Analysis

Risk Watch (PR Newswire, 1h ago): Headline references execution of a Contingent Value Rights agreement tied to potential priority review voucher value.
Market Wire (TradingView): Coverage of company estimates; no further detail in source.
Market Wire (Simply Wall St): Article questioning the timing of profitability for the company; no company-specific figures provided.
Risk Watch (Investing.com): Headline states the company executed a CVR agreement for voucher proceeds.
Catalyst (kalkine.ca): Reports the stock gained 9% in a session with no new announcement attached.
Market Wire (PR Newswire, 15h ago): Common stock to begin trading with stapled Contingent Value Rights after the close of business.

The butterfly supply-chain graph reports no supply-chain dependencies and no proprietary signals.

Open Questions

What specific products, pipeline programs, or regulatory milestones underpin the company's operations, given zero reported revenue?
What are the terms and potential value of the Contingent Value Rights and priority review voucher referenced in recent headlines?
What is the company's cash runway given FY 2025 free cash flow of $-29.8M against $41.3M of reported cash?
What is the complete debt position, since debt is listed as N/A in every reported period?
Why does the reported 52-week range span from $1.7 to $14.85, and what drove the decline to the current $2.23 price?

ATOS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Atossa Therapeutics Inc. (ATOS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ATOS Debate Forum (3) ↓

🔴 RISK WATCH PR Newswire • 3h ago

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

PR Newswire report covering Atossa Therapeutics Inc. (ATOS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 6h ago

Atossa Therapeutics, Inc. Estimates – NASDAQ:ATOS

TradingView report covering Atossa Therapeutics Inc. (ATOS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 9h ago

When Can We Expect A Profit From Atossa Therapeutics, Inc. (NASDAQ:ATOS)?

Simply Wall St report covering Atossa Therapeutics Inc. (ATOS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investing.com • 12h ago

Atossa Therapeutics executes CVR agreement for voucher proceeds

Investing.com report covering Atossa Therapeutics Inc. (ATOS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST kalkine.ca • 15h ago

Atossa Therapeutics (NASDAQ:ATOS): Penny Stock Gains 9% Today With No New Announcement Attached

kalkine.ca report covering Atossa Therapeutics Inc. (ATOS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE PR Newswire • 18h ago

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

PR Newswire report covering Atossa Therapeutics Inc. (ATOS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago

Definium Therapeutics, Inc. (DFTX) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Atossa Therapeutics Inc. (ATOS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 14d ago

Atossa Therapeutics Confirms Shares To Begin Trading With One Stapled Contingent Value Right As Of Close Of Business On October 19

Under the terms of the Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, each share of Atossa common stock outstanding at the close of business on

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ATOS Bull vs. Bear Conversation Board — What's Your Call at $2.17?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ATOS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.96 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ATOS (D- • RQD 35/100) a Buy at $2.23?

Welcome to the ATOS (Atossa Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.87 (-16.1%)

Spot @ $2.23

Pump the brakes on ATOS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ATOS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Atossa Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.65 (+18.8%)

Spot @ $2.23

ATOS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ATOS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.23 (52-wk range $1.70 - $14.85), any beat on forward guidance forces shorts and underweight funds to chase.